<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02612532</url>
  </required_header>
  <id_info>
    <org_study_id>LuCID-2</org_study_id>
    <nct_id>NCT02612532</nct_id>
  </id_info>
  <brief_title>Lung Cancer Indicator Detection</brief_title>
  <acronym>LuCID</acronym>
  <official_title>Lung Cancer Indicator Detection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Owlstone Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Papworth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals, Leicester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universit√§tsklinikum Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glenfield Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peterborough and Stamford Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals of North Midlands NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Manchester University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Buckinghamshire Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wirral University Teaching Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>South Tyneside NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aintree University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Research and Trials Unit (Norfolk &amp; Norwich University Hospital, UK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barnet and Chase Farm Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liverpool Heart and Chest Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Owlstone Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Lung Cancer Indicator Detection (LuCID) study investigates the the diagnostic accuracy of
      FAIMS for diagnosis of lung cancer by analysis of exhaled Volatile Organic Compounds.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale Approximately 75% of patients with lung cancer present with advanced disease. For
      those with stage 1 disease, the chance of cure is up to 70%. Therefore, diagnostics which may
      aid identification of those with early stage lung cancer will play an important role in
      future screening programs. Because all cancer cells are characterized by a change in their
      metabolism related to their uncontrolled growth, detection of the resulting metabolites may
      be a novel diagnostic tool for early stage lung cancer. Subsets of these metabolites are
      volatile and are exhaled as so-called volatile organic compounds (VOCs). Analysis of exhaled
      VOCs suggests they differ between patients with advanced lung cancer and healthy controls.
      The Lung Cancer Indicator Detection (LuCID) study aims to validate the use of a
      high-throughput breath analysis technique in a population of patients whom are clinically
      suspected of having lung cancer.

      Methods LuCID is an international, multi-center case-control study. Patients referred by
      their GP or treating specialist for a diagnostic work-up for lung cancer will be invited to
      participate in the study. A maximum of two thousand five hundred patients whom consent to
      partake in this study will be asked to provide a breath sample prior to any diagnostic
      procedures. This is a non-invasive procedure that will require the patient to breath normally
      into a facemask to collect 2.5L of breath amounting to approximately 10 minutes of breathing.
      The resulting samples will be analyzed for VOCs by Gas Chromatography coupled to Mass
      Spectrometry and Gas Chromotography coupled to Field Assymetrical Ion Mobility Spectrometry.
      The resulting VOC profiles will be used to generate a diagnostic algorithm in order to try to
      differentiate between patients with and without lung cancer in the intention to diagnose
      population. This study will not interfere in any with the standard care offered at the
      clinical sites.

      Outcomes The results of this study will provide detailed insights into the accuracy of the
      test for the detection of lung cancer in the intention to diagnose population. This will form
      the foundation for a subsequent study in a population at risk for the development of lung
      cancer. If sufficiently accurate for early stage disease, analysis of breath VOCs could help
      implement large-scale screening for lung cancer, significantly decreasing the morbidity and
      mortality of the disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve for the diagnostic algorithm for lung cancer with optimal point sensitivity, specificity negative and positive predictive values.</measure>
    <time_frame>2 years</time_frame>
    <description>Diagnostic accuracy of VOC analysis for Lung Cancer diagnosis based on pattern recognition analysis of raw VOC-spectra generated by Lonestar analysis of breath.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fraction of within group variability in exhaled VOCs explained by factors not primarily related to disease proces</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of potential parameters affecting exhaled VOCs other than lung cancer such as smoking, diet and co-morbidities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identified exhaled biomarkers associated with tumor stage and size.</measure>
    <time_frame>2 years</time_frame>
    <description>Analysis of correlation between exhaled biomarkers and the type, stage and size of the pulmonary tumor.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>LuCID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standardised exhaled volatile organic compound collection by &quot;ReCIVA&quot; breath sampler (http://www.owlstonenanotech.com/medical/products/reciva) for analysis of volatile organic compounds by Lonestar (http://www.owlstonenanotech.com/medical/products/lonestar)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ReCIVA breath sampler</intervention_name>
    <description>Device developed for standardised collection of breath samples http://www.owlstonenanotech.com/medical/products/reciva</description>
    <arm_group_label>LuCID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Recruitment for these patients will be done from NHS hospitals whom identify or follow-up
        on patients suspected of having lung cancer.

          -  Inclusion criteria:

               -  Older than 18 years at time of consent

               -  Referred for investigation due to suspicion of lung cancer

                    -  Referral based on suspicious symptoms

                    -  Referral based on suspicious finding on imaging, including CTscan with
                       indeterminate nodule requiring follow-up evaluation.

               -  Capable of understanding written and/or spoken language

               -  Able to provide informed consent

          -  Exclusion criteria:

               -  (Anticipated) inability to complete breath sampling procedure due to e.g. hyper-
                  or hypo-ventilation, respiratory failure or claustrophobia when wearing the
                  sampling mask

               -  Participating in a Clinical Trial Investigational Medicinal Product (CTIMP)

               -  Pulmonary function test with metacholine or beta-2-sympatico mimetic in last 2
                  hours.

               -  Any lung biopsy in the past 48 hours

               -  Currently undergoing anti-cancer treatment for lung cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc P van der Schee, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Owlstone Medical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc P van der Schee, MD, PhD</last_name>
    <phone>+01223 428200</phone>
    <email>marc.vanderschee@owlstone.co.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Boyle</last_name>
    <phone>+01223 428200</phone>
    <email>billy.boyle@owlstone.co.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZA University Hospital Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZG University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>PapworthHospital</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Rintoul, MD, PhD</last_name>
      <email>robert.rintoul@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Buckinghamshire Healthcare Trusts</name>
      <address>
        <city>Buckinghamshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anjani Prasad</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Hertfordshire Hospital NHS Trust</name>
      <address>
        <city>Hertfordshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Barlow</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Leicester</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Bennet, MD</last_name>
      <email>Jonathan.Bennett@uhl-tr.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Aintree NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seamus Grundy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samual Janes, MD, PhD</last_name>
      <email>s.janes@ucl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of South Manchester NHs Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Crosbie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospital NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Baldwin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peterborough and Stamford Hospital</name>
      <address>
        <city>Peterborough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Calvert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Tyneside District Hospital</name>
      <address>
        <city>South Shields</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liz Fuller</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serena Chee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital NHS Trust</name>
      <address>
        <city>Stoke</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Haris</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wirral University Teaching Hospital NHS Foundation Trust</name>
      <address>
        <city>Upton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Wight</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.owlstonenanotech.com/lucid</url>
    <description>LuCID study homepage</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

